(1R,2S)-rel-2-(3,4-Difluorophenyl)cyclopropanamine hydrochloride

Product Details

CAS No:1156491-10-9

MF:C9H9F2N.HCl

Appearance:white or off-white crystalline powder

Specification:98.5%

UN number:-

Package:1/5/10/25kgs/drum

Supply Capacity:Tons

Synonyms:(1R,2S)-2-(3,4-difluorophenyl)cyclopropanaMine Hydrochloride(1:1);(1R,2S)-2-(3,4-Difluorophenyl)-cyclopropan-1-aMine HCL;(1R trans)-2-(3,4-difluorophenyl)cyclopropane aMine hydrochloride;(1R,2S)-rel-2-(3,4-Difluorophenyl)cyclopropanami;2-(3,4-Difluoro-phenyl)-cyclopropylamine;CYCLOPROPANAMINE, 2-(3,4-DIFLUOROPHENYL)-, HYDROCHLORIDE (1:1), (1R,2S)-REL-;(1S,2R)-2-(3,4-difluorophenyl)cyclopropanaMine;trans-(1R,2S)-2-(3,4-difluorphenyl)cyclopropylaMine; 1156491-10-9; (1R,2S)-2-(3,4-difluorophenyl)cyclopropan-1-amine;hydrochloride; RefChem:393261; 829-852-9; (1R,2S)-2-(3,4-difluorophenyl)cyclopropanamine hydrochloride; 1402222-66-5; (1R,2S)-rel-2-(3,4-Difluorophenyl)cyclopropanamine hydrochloride; C9H10ClF2N; Cyclopropanamine, 2-(3,4-difluorophenyl)-, hydrochloride (1:1), (1R,2S)-rel-; MFCD16621157; (1R TRANS)-2-(3,4-DIFLUOROPHENYL)CYCLOPROPANE AMINE; (1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamine hydrochloride; (1R,2S)-2-(3,4-DIFLUOROPHENYL)CYCLOPROPAN-1-AMINE HYDROCHLORIDE; 1006614-49-8; Cyclopropanamine, 2-(3,4-difluorophenyl)-, hydrochloride (1:1), (1R,2S)-; (1R,2S)-2-(3,4-Difluoro-phenyl)-cyclopropylamine hydrochloride; Cyclopropanamine, 2-(3,4-diflu; (1S,2R)-2-(3,4-Difluorophenyl)-cyclopropanamine Hydrochloride; Ticagrelor EP Impurity E (hydrochloride); WL9Y2C88ZH; Ticagrelor EP Impurity E HCl; SCHEMBL15058586; SCHEMBL29786384; SCHEMBL31329562; HY-I0180A; WLZ3550; Ticagrelor Related Compound cent/; CS-M1888; CS-M2272; rel-(1R,2S)-2-(3,4-Difluorophenyl)cyclopropanamine hydrochloride; AKOS016004061; EX-7184; FD96534; 1402222-66-5(HCl Salt); AC-29734; AS-19951; PD213009; SY163264; DB-126228; D97169; EN300-196973; F226816; F567593; Z2298098006; (1R,2S)-2-(3,4-difluorophenyl)cyclopropanamine;hydrochloride; (1R,2S)-rel-2-(3,4-Difluorophenyl)cyclopropanamine hydrochlo; (1R,2S)-rel-2-(3,4-Difluorophenyl)cyclopropanaminehydrochloride; 2-(3,4-Difluorophenyl)cyclopropanamine hydrochloride, (1R,2S)-; rac-(1R,2S)-2-(3,4-difluorophenyl)cyclopropan-1-amine hydrochloride; trans-(1R,2S)-2-(3,4-difluorophenyl)cyclopropan-1-amine;hydrochloride

Product application:(1R,2S)-rel-2-(3,4-Difluorophenyl)cyclopropanamine hydrochloride,1156491-10-9,(1R,2S)-2-(3,4-Difluorophenyl)cyclopropanamine HCl,trans-2-(3,4-Difluorophenyl)cyclopropanamine hydrochloride,Ticagrelor intermediate,Ticagrelor side chain,Ticagrelor chiral amine,Ticagrelor USP RC A,P2Y12 receptor antagonist intermediate,Antithrombotic drug intermediate,Chiral cyclopropylamine derivative,Fluorinated chiral building block,Fine pharmaceutical intermediate,High enantiomeric purity intermediate,High purity (1R,2S)-rel-2-(3,4-Difluorophenyl)cyclopropanamine hydrochloride 99.5%,CAS 1156491-10-9 supplier,Ticagrelor side chain manufacturer China,Suzhou Health Chemicals specialty chemicals,Ticagrelor intermediate wholesale bulk export

 

(1R,2S)-rel-2-(3,4-Difluorophenyl)cyclopropanamine hydrochloride serves as an indispensable, ultra-pure chiral fluorinated cyclopropylamine intermediate, benchmark cardiovascular active pharmaceutical ingredient (API) building block, and versatile organofluorine synthon extensively utilized across modern antiplatelet drug manufacturing, oral antithrombotic agent total synthesis, novel P2Y12 receptor antagonist discovery, and fine chiral medicinal chemistry sectors. In cardiovascular pharmacology and process development, universally designated as trans-2-(3,4-difluorophenyl)cyclopropanamine hydrochloride, it functions as the foundational raw material for the commercial total synthesis of blockbuster oral antiplatelet therapeutics, most notably ticagrelor; its molecular architecture incorporates a rigid trans-cyclopropane core flanked by an asymmetric primary amine hydrochloride salt and a 3,4-difluorophenyl substituent, whose precise (1R,2S) stereochemical spatial orientation facilitates smooth, highly stereoselective nucleophilic displacement onto substituted dichlorotriazolopyrimidine heterocyclic cores; the inclusion of this rigid chiral cyclopropyl fragment alongside dense aromatic fluorine substitution maximizes allosteric binding complementarity to the platelet purinergic P2Y12 receptor, enabling direct, rapid, and reversibly active inhibition of ADP-induced platelet aggregation without necessitating hepatic metabolic bioactivation; this molecular configuration effectively protects against recurrent myocardial infarction and ischemic stroke while resisting oxidative metabolic clearance to deliver predictable pharmacokinetics and an improved clinical safety window. In synthetic medicinal chemistry and scaffold hopping campaigns, it represents an essential chiral synthon for introducing conformationally constrained, fluorinated cyclopropylamine pharmacophores into novel antithrombotic leads and neuroprotective candidates. Furthermore, in asymmetric synthesis research, chiral ligand design, and specialized fluorinated biochemical probes, chemical systems engineered from (1R,2S)-rel-2-(3,4-Difluorophenyl)cyclopropanamine hydrochloride deliver exceptional enantiomeric integrity, reliable coupling kinetics, and broad multi-industry performance.